Immuunkontrolepunt-inhibeerders is 'n klas medisyne wat met die immuunstelsel van die liggaam veg om kankerselle te beveg. Die meeste pasiënte reageer egter nie op hierdie terapieë nie. Daar is 'n nuwer klas medisyne wat twee proteïene teiken wat betrokke is by die onderdrukking van die liggaam se immuunrespons teen gewasse.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from kanker with the molecule M7824. These researchers are also undertaking trials with those suffering from pankreaskanker and those infected with HPV.
There are many other trials and experiments being taken to treat and kanker genees more effectively in different research institutes. This drug with a dual approach will be a boon in the behandeling van kanker, as with a single molecule, multiple therapies are included.
